Drug Trial Radar · NCT06975293
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
107
Planned (sponsor's estimate)
Start
May 5, 2025
Primary completion
Dec 29, 2027
Study completion Jun 29, 2028
Sponsor
- Lead sponsor
- STORM Therapeutics LTDIndustry
- Sponsor type
- Industry
- Collaborators
- Coherus Oncology, Inc.
- First posted
- May 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).
Conditions
- Solid Tumor
- Sarcoma
- Leiomyosarcoma
- Dedifferentiated Liposarcoma
Interventions
STC-15 in combination with toripalimabDrug
STC-15 in combination with toripalimab in 21-day cycles
STC-15 monotherapyDrug
STC-15 monotherapy in 21-day cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combination Cohorts: Safety and tolerability of STC-15 in combination with toripalimabTime frame: 6 months
- Phase 2 Monotherapy Cohorts: Antitumor activity of STC-15 monotherapyTime frame: 6 months
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of California, San Francisco
San Francisco, California · Recruiting
University of Miami-Sylvester Comprehensive Cancer Center
Miami, Florida · Not yet recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Northwell Health Cancer Institute
Lake Success, New York · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Not yet recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
NEXT Houston
Houston, Texas · Recruiting
NEXT Dallas
Irving, Texas · Recruiting
NEXT Oncology
San Antonio, Texas · Recruiting
The START Center
San Antonio, Texas · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.